Tango Therapeutics Inc (TNGX) Stock Price, Quote & News

Company Profile

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repress...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 320 4900

Website: www.tangotx.com

Address:

201 Brookline Avenue, Suite 901, Boston, United States

ZacksResearch Dec. 22 at 2:08 PM

Biotech's Big Comeback in 2025: Will These Stocks Maintain Momentum in 2026? 🚀 🔬 $EYPT shares soared 140.5% in 2025 with promising pipeline progress and strong data readouts. 💊 $ANIP's Cortrophin Gel sales jumped 70% in the first nine months of 2025, driving impressive growth. 🧬 $TNGX surged 163.8%, fueled by positive clinical data and strategic pipeline advancements. Discover the full analysis here 👉 https://www.zacks.com/stock/news/2807150/3-biotech-stocks-wall-street-analysts-are-bullish-on-for-2026?cid=sm-stocktwits-2-2807150-body-25740&ADID=SYND_STOCKTWITS_TWEET_2_2807150_BODY_25740

0 · Reply

ZacksResearch Dec. 22 at 1:08 PM

Biotech winners don’t fade — Wall Street’s lining up for 2026 🚀 $EYPT, $ANIP, and $TNGX put up a stellar show in 2025, and analysts are bullish that this momentum can carry into 2026 as well. Strong performance plus continued confidence is a combo investors can’t ignore. See why these three biotech names have analysts bullish heading into 2026 👉 https://www.zacks.com/stock/news/2807150/3-biotech-stocks-wall-street-analysts-are-bullish-on-for-2026?cid=sm-stocktwits-2-2807150-teaser-25738&ADID=SYND_STOCKTWITS_TWEET_2_2807150_TEASER_25738

0 · Reply

UgoGreg Dec. 18 at 10:28 PM

$TNGX https://youtu.be/ygBN8MilTyc

0 · Reply

McKenna14 Dec. 18 at 9:30 PM

$TNGX hmm what is going on ?

0 · Reply

Redbet69 Dec. 18 at 9:29 AM

$TNGX $AVXL $CCCC $CRDF

0 · Reply

JohnTrack Dec. 17 at 12:04 PM

$TNGX update rolling through now... https://www.rapidticker.com/news/tngx-tango-therapeutics-to-participate-in-0c5e70

0 · Reply

StockConsultant Dec. 15 at 1:23 PM

$TNGX Tango Therapeutics stock watch, nice trend with a pullback to 9.24 double support area and high trade quality at https://stockconsultant.com/?TNGX

0 · Reply

Liatris_spicata Dec. 13 at 2:08 AM

$TNGX Thank you for sharing this. So much promise here- and so little interest on ST.

0 · Reply

Ichigodoran Dec. 12 at 6:50 PM

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance $IMRX $ONCY $TNGX $RPRX $MRNA https://finviz.com/news/252943/pancreatic-cancer-survival-gains-accelerate-as-novel-therapies-advance

1 · Reply

Mikey6028 Dec. 5 at 2:54 PM

$TNGX $ASBP $SHMD I have shares in all 3 and also IVDA, which is primed and ready for a move. Take a look at the chart. Happy hunting fellow investors!

0 · Reply

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 7:00 AM EST - 4 weeks ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 21, 2025, 4:20 PM EST - 4 weeks ago

Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy

Oct 23, 2025, 5:07 PM EDT - 2 months ago

Tango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers Transcript

Oct 23, 2025, 11:17 AM EDT - 2 months ago

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Oct 23, 2025, 7:20 AM EDT - 2 months ago

Tango Therapeutics Announces $225 Million Financing

Oct 6, 2025, 7:00 AM EDT - 2 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Aug 26, 2025, 7:00 AM EDT - 4 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Jun 27, 2025, 7:00 AM EDT - 6 months ago

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

May 27, 2025, 7:00 AM EDT - 7 months ago

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 7 months ago

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

May 12, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 1, 2025, 7:00 AM EDT - 8 months ago

Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Feb 27, 2025, 7:00 AM EST - 10 months ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights

Jan 30, 2025, 7:00 AM EST - 11 months ago

Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference

Jan 23, 2025, 5:44 AM EST - 11 months ago

Tango Therapeutics: Chance For A Short Squeeze

Dec 3, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 27, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 7:05 AM EST - 1 year ago

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 6, 2024, 7:00 AM EST - 1 year ago

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Sep 10, 2024, 12:45 PM EDT - 1 year ago

Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data

Aug 28, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Participate in Upcoming Investor Conferences

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 23, 2024, 9:18 AM EDT - 1 year ago

Medivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program

May 23, 2024, 7:19 AM EDT - 1 year ago

Tango Therapeutics to stop development of cancer therapy

May 23, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Announces Discontinuation of TNG348 Program

May 8, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Mar 5, 2024, 4:47 PM EST - 1 year ago

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

Jan 31, 2024, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 25, 2024, 12:46 PM EST - 2 years ago

Tango Therapeutics: Making Its Way Into Clinic With 4 Innovative Cancer Drugs

Jan 4, 2024, 2:47 AM EST - 2 years ago

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Nov 13, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

Nov 8, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

Nov 7, 2023, 7:00 AM EST - 2 years ago

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

Oct 23, 2023, 6:26 PM EDT - 2 years ago

Circling Bank On Tango Therapeutics

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

Aug 29, 2023, 5:08 PM EDT - 2 years ago

Tango Therapeutics Announces Updates to Its Board of Directors

Aug 10, 2023, 7:30 AM EDT - 2 years ago

Tango Stock Surges On Peer Data Merits Excitement And Perspective

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces $80 million Private Placement Financing

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

Jul 26, 2023, 7:29 PM EDT - 2 years ago

Tango Therapeutics: Partial Phase 1 Data Has Not Helped

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

Jul 10, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

May 9, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Apr 18, 2023, 4:30 PM EDT - 2 years ago

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

Apr 3, 2023, 7:00 AM EDT - 2 years ago

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

ZacksResearch Dec. 22 at 2:08 PM

0 · Reply

ZacksResearch Dec. 22 at 1:08 PM

0 · Reply

UgoGreg Dec. 18 at 10:28 PM

$TNGX https://youtu.be/ygBN8MilTyc

0 · Reply

McKenna14 Dec. 18 at 9:30 PM

$TNGX hmm what is going on ?

0 · Reply

Redbet69 Dec. 18 at 9:29 AM

$TNGX $AVXL $CCCC $CRDF

0 · Reply

JohnTrack Dec. 17 at 12:04 PM

$TNGX update rolling through now... https://www.rapidticker.com/news/tngx-tango-therapeutics-to-participate-in-0c5e70

0 · Reply

StockConsultant Dec. 15 at 1:23 PM

$TNGX Tango Therapeutics stock watch, nice trend with a pullback to 9.24 double support area and high trade quality at https://stockconsultant.com/?TNGX

0 · Reply

Liatris_spicata Dec. 13 at 2:08 AM

$TNGX Thank you for sharing this. So much promise here- and so little interest on ST.

0 · Reply

Ichigodoran Dec. 12 at 6:50 PM

1 · Reply

Mikey6028 Dec. 5 at 2:54 PM

$TNGX $ASBP $SHMD I have shares in all 3 and also IVDA, which is primed and ready for a move. Take a look at the chart. Happy hunting fellow investors!

0 · Reply

JarvisFlow Dec. 4 at 4:59 PM

Stifel has adjusted their stance on Tango Therapeutics ( $TNGX ), setting the rating to Buy with a target price of 15.

0 · Reply

notreload_ai Dec. 4 at 4:25 PM

Stifel initiates coverage of $TNGX with a Buy rating and $15 target, citing strong potential for its PRMT5 inhibitor vopimetostat and forecasting $1.2B in peak global revenue by 2035. https://notreload.xyz/stifel-begins-coverage-of-tango-therapeutics-with-bullish-outlook/

1 · Reply

BEATOFtheMARKET Dec. 2 at 10:28 AM

$TMDX $TMFC $TMO $TNA $TNGX

0 · Reply

justiceforb_85 Dec. 1 at 7:12 PM

$TNGX added on this dip. Look forward to further data for vopimetostat in 2L MTAP-deleted NSCLC and PDAC.

0 · Reply

AnomalyDetective Nov. 29 at 8:55 PM

All new MDA breakout picks out for Week 49 with momentum gauges improving sharply. 💥 Last week the minimum returns of +17.59% beat the full year #SPX $SPY YTD returns +17.47% through 48 weeks. 💥 Week 48 MDA picks $PSNL $TNGX $ZYME $CLLS all broke 10% gains in the short trading week. New picks for next week. 👉 New selections here with only 3 full weeks of trading before prices increase for 2026! See the 93 picks in the past year gaining over 20% from selection: https://seekingalpha.com/mp/1201-value-momentum-breakouts/articles/6231448-december-mda-breakout-stocks-week-49-and-highlighted-top-gainers

0 · Reply

AnomalyDetective Nov. 26 at 2:00 PM

$PSNL up +38.1% through premarket in a strong breakout from Segment 2 negative acceleration. $TNGX +25.8% peak gains so far. 💥All four Week 48 MDA picks gained over 10% through Tuesday, up +17.98% together. 💥 Extending the count to 347 weeks with at least one of the picks gaining over 10% in less than a week. 💥 Simulated cumulative avg returns +283.8% YTD adding gains weekly, could also be compounded weekly. 👉New Week 49 MDA picks out today after the close for members in the short trading week. Credit: http://vmbreakouts.com @vmbreakouts

0 · Reply

Liatris_spicata Nov. 25 at 3:23 AM

$TNGX What do you make of that?

1 · Reply

tomwalt Nov. 24 at 9:31 PM

$TNGX Sold off most of its gains….

1 · Reply

Chauncy_Peppertooth Nov. 24 at 3:43 PM

$TNGX this things a monster

0 · Reply

Sixth_Sense Nov. 24 at 3:03 PM

$TNGX beast mode 💪

0 · Reply

AnomalyDetective Nov. 24 at 3:02 PM

$TNGX +22.4% through Monday for members in the Week 48 MDA selections up +14% in this short holiday trading week. Two picks up over 21% so far. @VMBreakouts

0 · Reply

AnomalyDetective Nov. 24 at 12:49 PM

$CLLS up another 10% premarket for members as the Week 48 MDA picks gain +10.22% with 3 out of 4 selections on track over 10% gains to start the short trading week. Selections extending the count to 346 weeks with at least one pick gain over 10% in less than a week. See prior chart on $TNGX and many more prior mda breakout stocks at http://top.vmbreakouts.com @VMBreakouts

0 · Reply

Market Cap	1.16B
Revenue (ttm)	42.07M
Net Income (ttm)	-130.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-309.72%
Debt to Equity Ratio	0.00

Volume	951,300
Avg Vol	3,461,996
Day's Range	N/A - N/A
Shares Out	134.68M
Stochastic %K	7%
Beta	1.71
Analysts	Strong Sell
Price Target	$13.22